title: Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice.
abstract: Duchenne muscular dystrophy (DMD), caused by mutations in the dystrophin gene, involves severe muscle degeneration, inflammation, fibrosis, and early death in afflicted boys. Matrix metalloproteinases (MMPs) are extracellular proteases that cause tissue degradation in several disease states. In this study, we tested the hypothesis that the expression levels of various MMPs are abnormally increased and that their inhibition will ameliorate muscle pathogenesis in animal models of DMD. Our results show that the transcript levels of several MMPs are significantly up-regulated, whereas tissue inhibitors of MMPs are down-regulated, in dystrophic muscle of mdx mice. Chronic administration of batimastat (BB-94), a broad spectrum peptide inhibitor of MMPs, reduced necrosis, infiltration of macrophages, centronucleated fibers, and the expression of embryonic myosin heavy chain in skeletal muscle of mdx mice. Batimastat also reduced the expression of several inflammatory molecules and augmented the levels of sarcolemmal protein beta-dystroglycan and neuronal nitric oxide in mdx mice. In addition, muscle force production in isometric contraction was increased in batimastat-treated mdx mice compared with those treated with vehicle alone. Furthermore, inhibition of MMPs using batimastat reduced the activation of mitogen-activated protein kinases and activator protein-1 in myofibers of mdx mice. Our study provides the novel evidence that the expression of MMPs is atypically increased in DMD, that their inhibition ameliorates pathogenesis, and that batimastat could prove to be a significant candidate for DMD therapy.
authors.affiliation: Department of Anatomical Sciences and Neurobiology, University of Louisville School of Medicine, 500 South Preston Street, Louisville, KY 40202, USA.
authors.forename: Akhilesh
authors.initials: A
authors.lastname: Kumar
authors.forename: Shephali
authors.initials: S
authors.lastname: Bhatnagar
authors.forename: Ashok
authors.initials: A
authors.lastname: Kumar
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D016189:Dystrophin / Q000235:genetics / Q000378:metabolism*; D005355:Fibrosis; D005786:Gene Expression Regulation; D006801:Humans; D007249:Inflammation / Q000276:immunology; D008297:Male; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D018101:Mice, Inbred mdx; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D008969:Molecular Sequence Data; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology / Q000502:physiology*; D020388:Muscular Dystrophy, Duchenne / Q000188:drug therapy* / Q000503:physiopathology; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D013876:Thiophenes / Q000494:pharmacology / Q000627:therapeutic use; D018808:Transcription Factor AP-1 / Q000378:metabolism
chemical_list: D016189:Dystrophin; D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors; D013876:Thiophenes; D018808:Transcription Factor AP-1; D010649:Phenylalanine; C080985:batimastat; D020928:Mitogen-Activated Protein Kinases; D020782:Matrix Metalloproteinases
references.citation: Nat Med. 2005 Jun;11(6):672-7
references.pmid: 15864313
references.citation: Adv Enzyme Regul. 1995;35:293-301
references.pmid: 7572350
references.citation: Pharmacol Ther. 1997;75(1):69-75
references.pmid: 9364582
references.citation: Am J Pathol. 2007 Feb;170(2):633-43
references.pmid: 17255331
references.citation: FEBS Lett. 2002 Jun 5;520(1-3):18-24
references.pmid: 12044863
references.citation: Biochemistry. 1995 Oct 31;34(43):14012-20
references.pmid: 7577999
references.citation: J Cell Biol. 1997 Oct 20;139(2):375-85
references.pmid: 9334342
references.citation: APMIS. 1999 Jan;107(1):174-80
references.pmid: 10190295
references.citation: Am J Pathol. 2008 Jun;172(6):1509-19
references.pmid: 18458097
references.citation: Oncology. 2005;69(1):35-43
references.pmid: 16088233
references.citation: Mol Cell Biochem. 2003 Nov;253(1-2):31-40
references.pmid: 14619953
references.citation: Lancet. 2002 Feb 23;359(9307):687-95
references.pmid: 11879882
references.citation: FASEB J. 2003 Mar;17(3):386-96
references.pmid: 12631578
references.citation: Int J Cancer. 1990 Aug 15;46(2):282-6
references.pmid: 2166712
references.citation: Hum Mol Genet. 2008 Aug 1;17(15):2280-92
references.pmid: 18430716
references.citation: J Mol Med (Berl). 2010 Feb;88(2):155-66
references.pmid: 19816663
references.citation: J Biol Chem. 1995 Jul 14;270(28):16483-6
references.pmid: 7622446
references.citation: Hum Mol Genet. 2009 Jul 15;18(14):2584-98
references.pmid: 19401296
references.citation: Neurology. 1999 Oct 22;53(7):1397-401
references.pmid: 10534241
references.citation: Biochem Biophys Res Commun. 2006 Jun 30;345(2):867-71
references.pmid: 16701552
references.citation: FASEB J. 2004 Jan;18(1):102-13
references.pmid: 14718391
references.citation: Nat Med. 1998 Dec;4(12):1441-4
references.pmid: 9846586
references.citation: Neuromuscul Disord. 2005 May;15(5):336-41
references.pmid: 15833425
references.citation: J Clin Invest. 1997 Jun 1;99(11):2745-51
references.pmid: 9169505
references.citation: J Cell Biol. 2010 Mar 22;188(6):833-49
references.pmid: 20308426
references.citation: Adv Dent Res. 1998 Nov;12(2):12-26
references.pmid: 9972117
references.citation: J Biol Chem. 2007 Nov 30;282(48):35113-24
references.pmid: 17897957
references.citation: Mol Biol Cell. 2003 Nov;14(11):4499-511
references.pmid: 14551255
references.citation: Neuromuscul Disord. 2001 Sep;11(6-7):556-64
references.pmid: 11525885
references.citation: Prostate. 2000 May 1;43(2):77-82
references.pmid: 10754522
references.citation: J Biol Chem. 2006 Apr 14;281(15):10327-36
references.pmid: 16461349
references.citation: Cancer Res. 1996 Jun 15;56(12):2815-22
references.pmid: 8665519
references.citation: Biochem Pharmacol. 2008 Jan 15;75(2):346-59
references.pmid: 17678629
references.citation: Biochim Biophys Acta. 2005 Jun 10;1740(3):326-31
references.pmid: 15949699
references.citation: Curr Opin Genet Dev. 2003 Jun;13(3):231-8
references.pmid: 12787784
references.citation: Muscle Nerve. 2001 Dec;24(12):1575-94
references.pmid: 11745966
references.citation: Semin Cell Dev Biol. 2008 Feb;19(1):61-8
references.pmid: 17693104
references.citation: Nat Rev Drug Discov. 2007 Jun;6(6):480-98
references.pmid: 17541420
references.citation: Clin Cancer Res. 1999 Mar;5(3):513-20
references.pmid: 10100701
references.citation: Nat Rev Mol Cell Biol. 2007 Mar;8(3):221-33
references.pmid: 17318226
references.citation: Clin Cancer Res. 1998 May;4(5):1101-9
references.pmid: 9607566
references.citation: J Clin Invest. 2004 Sep;114(5):623-33
references.pmid: 15343380
references.citation: Drug Resist Updat. 2004 Jun;7(3):195-208
references.pmid: 15296861
references.citation: Br J Cancer. 2002 Jul 15;87(2):161-7
references.pmid: 12107836
references.citation: Clin Cancer Res. 1996 Jul;2(7):1207-14
references.pmid: 9816289
references.citation: FASEB J. 2003 Sep;17(12):1579-84
references.pmid: 12958164
references.citation: Cell. 1995 Mar 10;80(5):675-9
references.pmid: 7889563
references.citation: Genes Dev. 2000 Sep 1;14(17):2123-33
references.pmid: 10970876
references.citation: Cancer Res. 1994 Sep 1;54(17):4726-8
references.pmid: 8062271
references.citation: Nat Rev Drug Discov. 2003 May;2(5):379-90
references.pmid: 12750741
references.citation: J Clin Oncol. 2001 Aug 1;19(15):3447-55
references.pmid: 11481349
references.citation: J Cell Biol. 1991 Dec;115(6):1685-94
references.pmid: 1757468
references.citation: Curr Pharm Des. 2007;13(3):333-46
references.pmid: 17313364
references.citation: Cancer Res. 1995 Aug 15;55(16):3629-33
references.pmid: 7627972
references.citation: Neurology. 1993 Apr;43(4):795-800
references.pmid: 8469343
references.citation: Anticancer Drugs. 2003 Nov;14(10):773-8
references.pmid: 14597870
references.citation: Neuromuscul Disord. 2004 Sep;14(8-9):483-90
references.pmid: 15336689
references.citation: J Biol Chem. 2007 Jun 1;282(22):16036-41
references.pmid: 17426029
references.citation: Arthritis Rheum. 2003 Jun;48(6):1742-9
references.pmid: 12794843
references.citation: J Clin Invest. 2007 Apr;117(4):889-901
references.pmid: 17380205
references.citation: Br J Cancer. 2002 Jun 17;86(12):1864-70
references.pmid: 12085177
references.citation: Hum Mol Genet. 2002 Feb 1;11(3):263-72
references.pmid: 11823445
references.citation: Ann Neurol. 2009 Jan;65(1):47-56
references.pmid: 19086074
references.citation: J Cell Biol. 2001 Oct 1;155(1):123-31
references.pmid: 11581289
references.citation: Clin Sci (Lond). 2007 Jan;112(1):43-9
references.pmid: 16939410
references.citation: Nature. 2008 Nov 27;456(7221):511-5
references.pmid: 18953332
references.citation: Eur J Vasc Endovasc Surg. 2005 Sep;30(3):259-62
references.pmid: 16009575
references.citation: Nature. 1991 Aug 8;352(6335):536-9
references.pmid: 1865908
references.citation: Nat Med. 2002 Feb;8(2):95
references.pmid: 11821877
references.citation: PLoS One. 2008;3(10):e3387
references.pmid: 18852886
references.citation: J Neuroimmunol. 1997 Feb;72(2):155-61
references.pmid: 9042108
references.citation: Eur J Surg Oncol. 1997 Dec;23(6):526-31
references.pmid: 9484924
references.citation: Eur J Oral Sci. 2001 Aug;109(4):209-21
references.pmid: 11531066
references.citation: Curr Biol. 2001 Aug 21;11(16):1278-82
references.pmid: 11525743
references.citation: J Natl Cancer Inst. 1985 Jul;75(1):99-103
references.pmid: 2989606
references.citation: Mol Cell Biochem. 2003 Nov;253(1-2):269-85
references.pmid: 14619979